PharmaCyte Biotech Inc (PMCB)

[DragonBear]

nothing to invest in here?-Correct!

How about 2 previous successful clinicals?

They don't exist. Instead one had two ad hoc studies by Lohr conducted in 1999, not sanctioned by the FDA.

1/3 of the normal chemo used to treat patients...less side effects as a result of less chemo in the body as the cell in box treatment placed the chemo right at the cancer site.

Lohr never ran a control arm of Metronomic Ifosfamide vs Metronomic Ifosfamide+CIABs. Without the control arm, there is no evidence the presence of CIABs are required. Also his studies were overall flocked up.

There is no evidence/data to suggest CIABs converts even a modest amount of the drug "right at the cancer site". Try the liver instead.

The results obtained in 1999 are inferior to current day 1st line treatments. Progress haven't stood still, while Kenny dilutes SH holdings, and pads his retirement account.

As for 2nd line PC, which is what the IND was filed for, it's even worse...Once again the challenge:

Provide the link(s) of published journal papers which indicates Metronomic Ifosfamide can readily diffuse through the more dense and developed stromal structure of the PC tumor in a 2nd line PC patient. Where it can overcome the high interstitial pressure , of a collapsing vascular structure , and degradation of the drug by stromal enzymes. Also find links that demonstrate a small amount of Ifosfamide that gets through, can damage quiescent cancer cells found in a hypoxic environment.

Hint: You won't find anything in Kenny PR pumps to answer the challenge.

and...yeah........nothing here.

Correct again!!!